Segment reporting

6 Months Ended

Jun. 30, 2022

Segment Reporting [Abstract]

Segment Reporting Disclosure

Segment reporting

The Company’s operating divisions are comprised of its U.S. dialysis and related lab services business (its U.S. dialysis business), its U.S. integrated kidney care business, its U.S. other ancillary services and its international operations (collectively, its ancillary services), as well as its corporate administrative support.

The Company’s separate operating segments include its U.S. dialysis and related lab services business, its U.S. integrated kidney care business, its U.S. other ancillary services, its kidney care operations in each foreign sovereign jurisdiction, and its equity method investment in the Asia Pacific joint venture (APAC JV). The U.S. dialysis and related lab services business qualifies as a separately reportable segment, and all other operating segments have been combined and disclosed in the other segments category. See Note 25 to the Company's consolidated financial statements included in the 2021 10-K for further description of how the Company determines and measures results for its operating segments.

The following is a summary of segment net revenues, segment operating margin (loss), and a reconciliation of segment operating margin to consolidated income before income taxes:

	Three months ended June 30,				Six months ended June 30,
	2022		2021		2022		2021
Segment revenues:
U.S. dialysis
Dialysis patient service revenues:
External sources	$	2,637,738	$	2,648,676	$	5,184,700	$	5,204,936
Intersegment revenues	19,410		21,247		41,568		48,190
U.S. dialysis patient service revenues	2,657,148		2,669,923		5,226,268		5,253,126
Other revenues:
External sources	6,113		6,345		12,078		12,961
Intersegment revenues	(21)		70		(10)		130
Total U.S. dialysis revenues	2,663,240		2,676,338		5,238,336		5,266,217
Other—Ancillary services
Dialysis patient service revenues	172,361		169,281		341,680		327,608
Other external sources	110,545		92,208		205,854		191,006
Intersegment revenues	—		—		—		4,294
Total ancillary services revenues	282,906		261,489		547,534		522,908
Total net segment revenues	2,946,146		2,937,827		5,785,870		5,789,125
Elimination of intersegment revenues	(19,389)		(21,317)		(41,558)		(52,614)
Consolidated revenues	$	2,926,757	$	2,916,510	$	5,744,312	$	5,736,511
Segment operating margin (loss):
U.S. dialysis	$	472,801	$	533,779	$	879,241	$	1,013,686
Other—Ancillary services	(9,113)		(17,808)		(41,418)		(29,668)
Total segment operating margin	463,688		515,971		837,823		984,018
Reconciliation of segment operating income to  consolidated income before income taxes:
Corporate administrative support	(30,973)		(25,495)		(66,800)		(50,940)
Consolidated operating income	432,715		490,476		771,023		933,078
Debt expense	(82,586)		(73,324)		(156,377)		(140,338)
Other (loss) income, net	(1,284)		15,188		(3,070)		16,356
Consolidated income before income taxes	$	348,845	$	432,340	$	611,576	$	809,096

Depreciation and amortization expense by reportable segment was as follows:

	Three months ended June 30,				Six months ended June 30,
	2022		2021		2022		2021
U.S. dialysis	$	160,612	$	159,856	$	322,632	$	315,802
Other—Ancillary services	10,564		9,833		21,488		19,588
	$	171,176	$	169,689	$	344,120	$	335,390

Expenditures for property and equipment by reportable segment were as follows:

	Six months ended June 30,
	2022		2021
U.S. dialysis	$	237,686	$	271,884
Other—Ancillary services	27,775		22,554
	$	265,461	$	294,438

 

A summary of assets by reportable segment were as follows:

	June 30, 2022		December 31, 2021
U.S. dialysis	$	15,325,222	$	15,375,000
Other—Ancillary services	1,775,353		1,746,488
Consolidated assets	$	17,100,575	$	17,121,488